Navigation Links
NicOx' Naproxcinod Phase 3 Results Presented at American College of Rheumatology
Date:11/12/2007

ts were at least 40 years old, with a clinical diagnosis of primary osteoarthritis of the knee of at least 3 months duration, confirmed by radiographs, and diagnosed according to the ACR guidelines (patients must qualify as ACR global functional status I, II or III). Eligible patients were also current users of Non-Steroidal Anti-inflammatory Drugs (NSAIDs) or acetaminophen (paracetamol) for their osteoarthritis pain and these analgesics were withdrawn before treatment with study-drug. The study enrolled both hypertensive and non-hypertensive patients (50.3% of enrolled patients were hypertensive at baseline). There were no statistically significant differences among the four treatment groups for any baseline variables, including hypertension medical history.

About naproxcinod

Naproxcinod is in phase 3 clinical development for the treatment of the signs and symptoms of osteoarthritis. Two remaining pivotal phase 3 trials for naproxcinod (the 302 and 303 studies) are currently ongoing and efficacy results are expected to be reported in mid-2008. The Company will conduct a statistical analysis according to a predefined plan on the pooled OBPM data from the three phase 3 studies (301, 302 and 303), following the completion of the 302 and 303 studies. NicOx anticipates filing a New Drug Application for naproxcinod in the United States during the first quarter of 2009.

NOTE: Within the framework of the ACR annual meeting held in Boston from November 6 to 11, 2007, NicOx had a corporate booth to introduce the Company and its technology to the scientific and medical community in the United States.

NicOx (Bloomberg: COX:FP, Reuters: NCOX.PA) is a product-driven biopharmaceutical company dedicated to the development of nitric oxide- donating drugs to meet unmet medical needs. NicOx is targeting the therapeutic areas of inflammation and cardio-metabolic disease. Resources are focused on two lead compounds, naproxcinod (formerly HCT 3012), in phase 3 de
'/>"/>

SOURCE NicOx S.A.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. NicOx Reports TOPIGEN to Advance TPI-1020 Into Phase 2 for COPD Following Promising Clinical Results
2. NicOx and Ferrer Present Promising Clinical and Preclinical Results in Dermatology
3. NicOx Naproxcinod ABPM Data Presented at American Heart Association
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
6. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
7. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
10. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
11. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... 2014 The Cardinal Health 2014 digital ... can learn about the company,s fiscal year ... the health care continuum by accessing the ... Photo- http://photos.prnewswire.com/prnh/20140930/149504-INFO ... chief executive officer,s letter to shareholders, the ...
(Date:10/1/2014)... NEW YORK , October 1, 2014 ... service provider for the medical industries, announced today the expansion of ... New York City . genae Americas was incorporated in ... strategically centered in one of the highest concentrations of medical innovation ... Kassab , President at genae Americas. "The expansion of genae from ...
(Date:10/1/2014)...  Express Scripts (NASDAQ: ESRX ) today ... Medicare ® Prescription Drug Plans (PDP) will offer ... WAG ) (NASDAQ: WAG ), helping ...  for their Medicare dollars. Medicare beneficiaries who ... or Choice plans for 2015 can save ...
Breaking Medicine Technology:Cardinal Health 2014 Digital Report to Shareholders Now Available 2genae Opens Offices in New York City 2Express Scripts Collaborates with Walgreens to Create Value-Driven Medicare Prescription Drug Plan Pharmacy Network 2Express Scripts Collaborates with Walgreens to Create Value-Driven Medicare Prescription Drug Plan Pharmacy Network 3Express Scripts Collaborates with Walgreens to Create Value-Driven Medicare Prescription Drug Plan Pharmacy Network 4
... EAST RUTHERFORD, N.J., Nov. 1, 2011 Cambrex Corporation ... 2011 financial results will be released on Thursday, November ... The Company will host a conference call to discuss ... Conference CallWhen: , Friday, November 4, 2011 at 8:30 ...
... 2011 Takeda Global Research & Development ... Drug Administration (FDA) has assigned a Prescription Drug User ... for the review of its investigational type 2 diabetes ... combines alogliptin with pioglitazone in a single tablet.   ...
Cached Medicine Technology:Takeda Announces PDUFA Action Date for Investigational Type 2 Diabetes Therapies Alogliptin and the Fixed-Dose Combination Alogliptin/Pioglitazone 2Takeda Announces PDUFA Action Date for Investigational Type 2 Diabetes Therapies Alogliptin and the Fixed-Dose Combination Alogliptin/Pioglitazone 3
(Date:10/1/2014)... scientists has shown that more than 80 per cent ... , The study found that medicines called ,JAK inhibitors, ... mutation that is present in more than 80 per ... used, or are in clinical trials, for diseases including ... Bowel cancer is the second-most common cancer in Australia ...
(Date:10/1/2014)... of the human eye, the brain of a rat ... new technology, says a QUT leading robotics researcher. ... Faculty says the new study uses new computer algorithms ... buildings or tunnels. , "This is a very Frankenstein ... two halves of a thing together because we,re taking ...
(Date:10/1/2014)... Philadelphia, PA, October 1, 2014 Patients with ... treatment, have a greatly increased risk of depression. ... therapy for chronic hepatitis C virus infection causes ... Omega-3 fatty acids, more commonly known as fish ... including lowering the risk of heart disease and ...
(Date:10/1/2014)... New research suggests the adage that encourages people to ... target when it comes to exercise. When walking, staying ... distance to it appear shorter and help people walk ... compares this technique to walking while looking around the ... quality of exercise. , "People are less interested in ...
(Date:10/1/2014)... 2014 Marriagelifeinsurance.com has released a ... for retired couples. , Senior citizens can purchase ... for their loved ones. A joint policy is cheaper, ... pass away. , Life insurance can be used ... can even be purchased online, as the application process ...
Breaking Medicine News(10 mins):Health News:Eighty percent of bowel cancers halted with existing medicines 2Health News:Robot researcher combines nature to nurture 'superhuman' navigation 2Health News:Omega-3 fatty acids may prevent some forms of depression 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 3Health News:Elderly Life Insurance - Find Life Insurance for Retired Couples! 2
... , , AUSTIN, Texas, ... processing expert, ThermoGenesis Corp., to deliver the most sophisticated point ... innovative MarrowXpress(TM) (MXP(TM)) System defines a new standard for isolation ... MXP System consistently yields high (> 90%) mononuclear cell recovery ...
... Global health organization PSI helps contestants spread HIV prevention messages throughout ... 21 The Miss Universe contestants continued preparations for Sunday night,s ... condoms to test their strength and playing "Wild Fire Infection" games ... are part of an HIV peer education workshop designed by PSI ...
... , , KUALA LUMPUR, ... Technologies (ICT) is essential for modern healthcare delivery systems if ... and improve patient safety. , , (Logo: ... years, the acquisition of computer technologies by healthcare organizations has ...
... treatment to thousands who need it, experts say ... with patient and therapist texting each other in real-time ... of patients new access to much-needed treatment, researchers say. ... of research and practice involving technology-based treatments for depression ...
... , , , ... (Nasdaq: HTWR - ASX: HIN) today announced that HeartWare has surpassed ... marking an important early enrollment milestone. , , ... at the Texas Heart Institute in Houston, Texas by O.H. Frazier, ...
... N.Y. The Bioproduction Facility at Cornell University has ... vaccinethat will be used in clinical trials for patients ... was developed as a partnership between The Ludwig Institute ... trial is being conducted at New York University Medical ...
Cached Medicine News:Health News:Celling Technologies Sets New Standards With Sophisticated Adult Stem Cell Device 2Health News:Celling Technologies Sets New Standards With Sophisticated Adult Stem Cell Device 3Health News:Miss Universe Contestants Enter Condom Olympics to Tackle HIV 2Health News:Miss Universe Contestants Enter Condom Olympics to Tackle HIV 3Health News:Frost & Sullivan: Medico Legal Implications Related to the Usage of Electronic Health Record 2Health News:Frost & Sullivan: Medico Legal Implications Related to the Usage of Electronic Health Record 3Health News:Frost & Sullivan: Medico Legal Implications Related to the Usage of Electronic Health Record 4Health News:Web-Based Psychotherapy Can Work 2Health News:Web-Based Psychotherapy Can Work 3Health News:HeartWare International Surpasses 50 Implants in the US 2Health News:HeartWare International Surpasses 50 Implants in the US 3Health News:Cornell makes cancer vaccine for clinical use 2Health News:Cornell makes cancer vaccine for clinical use 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: